1. Scrip
  2. >>COVID-19

Pfizer Sees Expanded Access To Paxlovid With Pharmacist Prescribing

 
• By Jessica Merrill

Giving prescribing authority to pharmacists could improve access to the antiviral for patients at high risk for severe COVID-19. Comirnaty financial outlook is also strengthened based on new US contract.

pharmacist
FDA expands Paxlovid prescribing to pharmacists • Source: Shutterstock

In a move designed to expand access to the oral COVID-19 antiviral treatment, the US Food and Drug Administration has authorized pharmacists to prescribe Pfizer Inc.'s Paxlovid (nirmatrelvir/ritonavir) under certain conditions. Paxlovid has emerged as the leading treatment to prevent COVID-19 from worsening in patients at high risk of severe outcomes, but prescribing restrictions and the logistics of getting the treatment to patients within five days after symptoms begin have limited use of the treatment.

The FDA's Center for Drug Evaluation and Research (CDER) announced the revision to the emergency use authorization (EUA) for Paxlovid...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

 
• By Kevin Grogan

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine

 
• By Kevin Grogan

A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.

More from Scrip

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

 
• By Jessica Merrill

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.